St. Jude Medical announces CE Mark approval of Assura defibrillators St. Jude Medical announced European CE Mark approval of the Assura portfolio of implantable cardioverter defibrillators and cardiac resynchronization therapy defibrillators.
Leerink medical devices analyst holds an analyst/industry conference call Medical Devices Analyst Antalffy discusses the ultimate market opportunity for leadless pacers and compares Medtronic vs St. Jude Medical on an Analyst/Industry conference call to be held on September 24 at 2 pm.
St. Jude Medical recent weakness a buying opportunity, says Barclays Barclays said St. Jude Medical weakness is a buying opportunity. The analyst said CardioMEMS is underappreciated by the Street and valuation compelling given sequential revenue growth. Shares are Overweight rated.